Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01435122 · OUTCOME

Tumor Response Rate

A Study of Axitinib in Advanced Carcinoid Tumors · Source last updated 2018-10-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
12 Months

What was measured

Tumor response rate using RECIST. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Analysis population: All participants evaluable at time of analysis.

Groups in this outcome

Axitinib Administration

The investigational drug used in this study is axitinib, and is available as tablets.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Axitinib Administration22

Reported measurements

Source class 1

Partial response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Axitinib Administration1Not reportedNot reportedNot reportedNot reported

Stable disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Axitinib Administration21Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      title
      Partial response
    2. measurements
      1. group Id
        OG000
        value
        21
      title
      Stable disease
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Tumor response rate using RECIST. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
groups
  1. description
    The investigational drug used in this study is axitinib, and is available as tablets.
    id
    OG000
    title
    Axitinib Administration
param Type
COUNT_OF_PARTICIPANTS
population Description
All participants evaluable at time of analysis.
reporting Status
POSTED
time Frame
12 Months
title
Tumor Response Rate
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice